Aesthetic Medicine Panel: Regulatory Compliance, Longevity Medicine, and Complication Management
AHPRA and TGA Regulations Regarding Patient Portals and Advertising
General Principles of Advertising Compliance: * Any information accessible by the public is legally considered current advertising. This includes: * Posters on clinic walls. * On-hold messages played over the phone. * Information on a website or a ten-year-old blog post. * Advertising rules are distinct from communication within the confines of a professional consultation or treatment, which remains private correspondence.
Patient Portals as Advertising Channels: * Patient portals are generally considered advertising if they contain general information accessible to anyone with a login. * The "Speed Camera" Metaphor: Drew likens the regulatory environment to roads with speed cameras. Just as some drivers go in a zone and others go or , practitioners exhibit varying levels of adherence. Regulators (AHPRA and TGA) may not see every instance unless they have a specific reason to investigate.
Establishing a Doctor-Patient Relationship via Portals: * A login or an application for access alone is not sufficient to determine that a doctor-patient relationship exists in a way that exempts content from advertising rules. * A line of defense against advertising allegations exists if the practitioner can demonstrate that the patient has already attended the clinic and the information provided is response-based or specific to their care. * To truly circumvent public advertising classifications, a portal would need to operate on a "per-patient basis." * This means every patient's access must be unique to the treatments they have received and the prescriptions provided to them specifically. * Common portal setups featuring blanket passwords, unique sign-up links, or generic video/marketing/offer sections are classed as advertising.
Advertising and Regulatory Risks in Longevity Medicine
The Landscape of Longevity Medicine: * Longevity medicine (including peptides and IV treatments) is a booming industry but carries high regulatory risk from the TGA and AHPRA. * Specific cautions apply to marketing Intravenous (IV) therapies. Regulators are increasingly active in this space; some clinics have undergone audits for seemingly innocuous claims regarding Vitamin C injections.
Prohibited Advertising Claims: * Claims that a treatment will help a patient "live longer," "have more energy," "lighten or brighten skin," or "slow down aging" are prohibited. * TGA is currently more aggressive than AHPRA in pursuing clinics making these longevity-related claims.
Risk Metrics and Enforcement: * Approximately of current advertising audits handled by Drew's firm are associated with longevity clinics, despite there being far fewer longevity clinics than standard cosmetic clinics. * The regulatory focus on longevity is currently comparable to the heavy wave of enforcement seen when surgical advertising guidelines were released approximately years ago. * Penalties for advertising IV therapies can be more draconian than penalties for surgical negligence. Drew notes instances where doctors faced harsher consequences for IV marketing than a surgeon did for gross negligence or using non-TGA registered devices.
Clinical Perspectives on Longevity and Peptides
Metrics of Success and Research Gaps: * Unlike disease-based medicine, it is difficult to determine outcomes in longevity because there is a lack of established data and metrics of success. * Measurements for peptides, stem cells, and exosomes are difficult to quantify against potential risks.
Patient Safety and Access: * If physicians do not offer longevity education, patients may access substances via unregulated sources (e.g., companies in China) without understanding third-party testing, dosages, or contraindications.
High-Priority "Big Ticket" Items in Longevity: * Instead of "fancy peptides" for skin brightening, the panel suggests focusing on: * Metabolic Dysfunction: Managed via GLP-1 agonists. * Mobility/Sarcopenia Prevention: Maintaining the ability to exercise to prevent conditions like pneumonia in older age. * Hormonal Health: Managing perimenopause and menopause.
Legal Protections for Off-Label Peptides (Larissa’s Strategy): * Peptides are largely off-label and often compounded. * To protect against regulatory action, practitioners can frame treatments as "experimental" within a clinical research framework. * Steps for compliance: * Apply for commercial ethics committee approval (e.g., through Blueberry or Glide). * Obtain ethics-approved informed consent stating the treatment is experimental. * Only advertise information that is ethics-committee approved.
Specific Peptides Mentioned: * Tesamorelin: Historically used in the HIV community for lipodystrophy; has significant FDA research backing. * GLP-1s: Long-standing use for metabolic health.
Complications: The Case of Trans-Antral Temporal Filler
Case Details (Kath Portfolio): * Instrument: needle (packaged with the filler). * Event: The needle went "needle on bone," but penetrated the orbit because the temporal bone was thin. * Anatomical Findings: Kath demonstrated using a real human skull (not plastic) that the bone in the temporal fossa can be extremely thin. * Patient Factors: A history of domestic violence was noted in the medicolegal report; social work entries suggested this history might contribute to diastasis (separation) of suture lines in the temporal area, facilitating easier penetration.
Risk Management in Temple Augmentation: * Aspiration Debate: Relying on a negative aspirate as a safety measure is flawed. Practitioners may feel a false sense of security and inject more or faster if they do not see blood, despite the risk of an occlusion still being present. * Monocular Vision: If a patient has poor vision or is blind in one eye, high-risk areas like the temple, tear trough, A-frame, or glabella should be avoided entirely. * Blood Vessel Variation: There is an estimated anatomical variance in the vasculature of the face, meaning textbooks are not always reliable guides.
The Role and Limitations of Ultrasound in Aesthetic Medicine
Utility in Complication Management: * Ultrasound is most effective for resolving vascular occlusions (VO). It allows for targeted delivery of Hyalase (), requiring fewer units than the "random flooding" technique.
Limitations of Handheld Devices: * Handheld/pocket devices often have low frequency and cannot always visualize significant vasculature if the vessels are smaller than . * Over-reliance on low-quality ultrasound can lead to a false sense of security ("going rogue").
Competency and Training: * Ryan Shannon suggests it takes to years of consistent scanning ( to hours daily) and clinical attachments with radiologists to become truly competent. * Settings must be optimized for different areas (e.g., nose vs. glabella) to visualize minute blood vessels.
Educational Standards: The Graduate Certificate in Cosmetic Medicine
Curriculum Evolution: * The course is under a continuous quality improvement (CQI) process regulated by the Australian Skills Quality Authority (ASQA). * New content updates will include longevity medicine and ultrasound guidance.
Technological Improvements: * Release of a new Learning Management System (LMS) for better presentation. * Integration of AI tools to update content quickly and improve voiceover quality/pronunciation.
Competency-Based Assessment: * Assessment follows a "Satisfactory" or "Not Satisfactory" model. If a single question is wrong (e.g., regarding advertising laws), the student is not deemed competent until corrected. * The AMC is expected to "sharpen the pencil" and mandate specific competency-based training bars (like the Graduate Certificate) for non-surgical cosmetic procedures in the near future.
Delayed Onset Nodules (DONs) and Biofilms
Etiology: * Nodules are often theoretical and result from a combination of immunological reactions (foreign body response) and infective components (low-grade biofilms). * Biofilms: Slow-developing infections that form around the filler. * Granulomas: These require histological diagnosis for confirmation.
Patient Risk Factors: * Autoimmune conditions heighten the immune system and increase risk (e.g., Celiac disease, arthritis). * Recent illnesses or dental procedures increase the likelihood of inflammatory responses.
Data and Reporting (AMET/AMAT): * Data suggests no single product is significantly more likely to cause nodules; reporting rates are often skewed by a product's market share (more sales lead to more reported complications).
Questions & Discussion
Question (Audience): Can a recording explaining a procedure be shared with a patient via video, or does that become public advertising if they forward it? * Response (Drew): If created specifically for a patient, it is patient correspondence. However, if the video is generic for "prospective patients," it is marketing. Using language like "fixing rosacea" is considered body shaming by AHPRA and must be avoided. The safest way is to provide it through a controlled patient portal.
Question (Audience): Are there specific products that make delayed onset nodules more likely? * Response (Elena/Kath): Biocompatible fillers are less likely to be seen as foreign than permanent fillers, but all elicit an immune response. Data from AMET shows that patient factors (immune state) and practitioner factors (aseptic technique) are more significant than product factors.
Question (Audience): What was the indemnity outcome of the temple filler case? * Response (Kath): Kath was not privy to the final indemnity outcome; she only provided the medicolegal report.